India News Magazine

Angioimmunoblastic T-Cell Lymphoma Market Report Insights

 Breaking News
  • No posts were found

Angioimmunoblastic T-Cell Lymphoma Market Report Insights

January 27
13:46 2021
Angioimmunoblastic T-Cell Lymphoma Market Report Insights

DelveInsight’s “Angioimmunoblastic T-Cell Lymphoma Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Angioimmunoblastic T-Cell Lymphoma, historical and forecasted epidemiology as well as the Angioimmunoblastic T-Cell Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
DelveInsight’s “Angioimmunoblastic T-Cell Lymphoma Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Angioimmunoblastic T-Cell Lymphoma, historical and forecasted epidemiology as well as the Angioimmunoblastic T-Cell Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

What is Angioimmunoblastic T-Cell Lymphoma?

Angioimmunoblastic T-Cell Lymphoma (AITL) is a rare form of non-Hodgkin lymphoma, which is a group of related malignancies (cancers) that affect the lymphatic system (lymphomas).

How many people are affected by Angioimmunoblastic T-Cell Lymphoma?

  • As per DelveInsight estimates, the incident cases of Peripheral T-Cell Lymphoma (PTCL) in the 7MM was 16,298 cases in 2017. These cases are expected to increase at a significant rate during the forecast period.
  • Estimates suggested that the United States accounts for 37.5% of all incident cases of PTCL among the 7MM. In 2017, there were a total of 6,110 incident cases of PTCL in the US, which are anticipated to increase during the forecast period (2020-2030).
  • The United States had the highest percentage of incidence of AITL in 2017.

How will Angioimmunoblastic T-Cell Lymphoma Market change in upcoming years?

 

 

According to DelveInsight, Angioimmunoblastic T-Cell Lymphoma market in 7MM is expected to change in the study period 2017-2030.

AITL is one of the most common types of PTCL, typically present with advanced disease, systemic symptoms, and immune deregulation. Treatment can be challenging owing to frequent relapses after initial and subsequent therapy. The choice of front-line treatment depends on the goal of therapy. For most AITL patients, the initial goal of treatment is curative; therefore, an aggressive approach with combination chemotherapy followed often by consolidation with autologous stem-cell transplant (ASCT) is used. For elderly patients or those with significant comorbidities, milder therapy (such as corticosteroids with or without low-dose chemotherapy) may be appropriate. Although this approach is not curative, it does provide the potential for prolonged disease control and maintenance of the quality of life. Options in this scenario include intermittent courses of single-agent prednisone, combination chemotherapy (such as low-dose cyclophosphamide and etoposide combined with prednisone) or single-agent chemotherapy (Romidepsin, Belinostat, Pralatrexate, Bendamustine, Brentuximab vedotin, Cyclosporine A, Lenalidomide, Gemcitabine and others) or relapsed or refractory disease. These treatments can often suppress the symptoms that accompany AITL; typically, however, ongoing therapy is required at some frequency for maintenance of disease control.

 

For free sample pages, request here @ https://www.delveinsight.com/sample-request/angioimmunoblastic-t-cell-lymphoma-atcl-market

 

Overall, the Angioimmunoblastic T-cell Lymphoma (AITL) therapeutics market is further expected to increase by the major drivers, such as the rising incident population, technological advancements in the upcoming years.

Key players, such as Celgene, Verastem, Beigene, Merck, Solasia Pharma, Kura Oncology and others are involved in developing drugs for Angioimmunoblastic T-cell Lymphoma (AITL).

 

Scope of the Report

• The report covers the descriptive overview of Angioimmunoblastic T-Cell Lymphoma, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies

• Comprehensive insight has been provided into the Angioimmunoblastic T-Cell Lymphoma epidemiology and treatment in the 7MM

• Additionally, an all-inclusive account of both the current and emerging therapies for Angioimmunoblastic T-Cell Lymphoma are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape

• A detailed review of Angioimmunoblastic T-Cell Lymphoma market; historical and forecasted is included in the report, covering drug outreach in the 7MM

• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Angioimmunoblastic T-Cell Lymphoma market

The Angioimmunoblastic T-Cell Lymphoma market report provides current treatment practices, emerging drugs, Angioimmunoblastic T-Cell Lymphoma market share of the individual therapies, current and forecasted Angioimmunoblastic T-Cell Lymphoma market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Angioimmunoblastic T-Cell Lymphoma treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

 

For free sample pages, request here @ https://www.delveinsight.com/sample-request/angioimmunoblastic-t-cell-lymphoma-atcl-market

 

Media Contact
Company Name: DelveInsight
Contact Person: DelveInsight
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/


Warning: count(): Parameter must be an array or an object that implements Countable in /home/indoreonlinejour/indianewsmagazine.in/wp-content/themes/legatus-theme/includes/single/post-tags.php on line 5
Share